Allogene Q2 FY26 net loss narrows to $42.68 million; revenue rises to $4.64 million - ALLO News | RalliesAllogene Q2 FY26 net loss narrows to $42.68 million; revenue rises to $4.64 million
A
ALLO• Cash position and outlook
- Cash, cash equivalents and investments rose to USD 423.6 million at June 30, projecting runway into 2029.
- Allogene said 2026 operating expense is seen near USD 165 million.
Q2 FY26 financial results
- Allogene posted a Q2 2026 net loss of USD 42.7 million, narrowing from USD 50.94 million a year earlier.
- Loss per share improved to USD 0.13 from USD 0.23 in Q2 2025.
- Revenue rose to USD 4.64 million.
- Research and development spending fell to USD 30.72 million from USD 40.16 million year over year.
- General and administrative costs climbed to USD 20.84 million from USD 14.28 million.
ALPHA3 and cema-cel update
- The interim futility review showed MRD negativity of on versus on observation, a gap.
ALPHA3
58.3% (7/12)
cema-cel
16.7% (2/12)
41.6 percentage-point
The FDA granted RMAT and Fast Track designations for cema-cel as first-line consolidation in high-risk LBCL.Site activation target moved up by six months, with about 100 sites expected active by year-end.The next ALPHA3 update is slated for mid-2027.•
